Multiple Asia-based pharma companies are releasing new clinical data on pipeline oncology assets at the American Society of Clinical Oncology meeting in Chicago, and non-small cell lung cancer (NSCLC) and antibody-drug conjugates (ADCs) are emerging as early themes.
Lung Cancer, Conjugates Emerge As Key Asia Company Themes
Among Asia Pacific pharma companies presenting new clinical data on their oncology pipelines at ASCO, lung and urothelial cancer and antibody-drug conjugates emerge as stand-out themes.
